Articles - Therapeutic Options & Guidelines for Early Breast Cancer

Curated selection of peer-reviewed articles focusing on Breast Cancer advancements in the Asia-Pacific (APAC) region.

This curated selection of research articles provides a broad overview of breast cancer treatments, including reviews of standard practices, emerging therapies, and clinical guidelines.
The collection spans topics such as neoadjuvant treatments, management of metastatic cases, immunotherapy advances, and the efficacy of radiotherapy. It also examines the role of targeted therapies and systemic treatments for different breast cancer subtypes, offering valuable insights into the current state and future directions of breast cancer care.

Breast cancer highlights from 2023: Knowledge to guide practice and future research

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline

Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?

The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis

Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?

Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Breast cancer treatment: A phased approach to implementation

Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges

Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression

Breast Cancer Treatment
A Review

Articles - Therapeutic Options & Guidelines for Early Breast Cancer

Breast cancer highlights from 2023: Knowledge to guide practice and future research

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline

Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?

The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis

Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?

Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer

Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer

Immunotherapy in breast cancer: an overview of current strategies and perspectives

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice

Progress and challenges of immunotherapy in triple-negative breast cancer

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Breast cancer treatment: A phased approach to implementation

Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges

Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression

Breast Cancer Treatment
A Review

Articles - Therapeutic Options & Guidelines for Early Breast Cancer

Start typing and press enter to search